ATRC - エイトリキュア （AtriCure Inc.） エイトリキュアATRCのチャート
ATRCの企業情報
| symbol | ATRC |
|---|---|
| 会社名 | AtriCure Inc （エイトリキュア） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 アトリキュア（AtriCure Inc.）は心房細動（Afib）ソリューション会社である。同社は主に心臓組織の外科的アブレーション用に設計されたデバイスと、左心耳を除外するように設計されたシステムを開発、製造、販売している。これには、一定の開放的な手技を受けている患者の永続的かつ永続的な形態のAfibの治療用のIsolator Synergy Ablation Systemを含む、心臓組織の切除用の各種の製品ラインがある。それには、ラジオ周波数アブレーションデバイスおよびcryoICEクリオアブレーションシステム、および左心耳の除外用の製品ラインを含む、心臓組織アブレーションのための2つの主要な製品ラインがある。同社はまた、Lumitip解剖器具および再使用可能な心臓手術（弁）器具のEstechラインを販売している。そのcryoICE凍結手術製品ラインは多様な凍結切除装置を提供する。AtriClip左心房付属器排除システムは、心臓の左心耳（LAA）を閉塞するように設計されている。 エイトリキュアは、米国の医療機器メ―カ―。主な製品は、双極高周波電気メスシステム｢AtriCure RF｣、心房細動治療用チタン製クリップ｢AtriClip｣、電気手術システム｢Synergy｣など。北米、欧州、アジアで製品を販売する。本社は、オハイオ州ウエストチェスタ―。 AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure's Isolator ® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure's AtriClip ® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. |
| 本社所在地 | 7555 Innovation Way Mason OH 45040 USA |
| 代表者氏名 | Scott William Drake スコット・ウィリアム・ドレイク |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 513-755-4100 |
| 設立年月日 | 36800 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2005年 |
| 従業員数 | 570人 |
| url | www.atricure.com |
| nasdaq_url | https://www.nasdaq.com/symbol/atrc |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -8.51300 |
| 終値（lastsale） | 32.53 |
| 時価総額（marketcap） | 1150317499.79 |
| 時価総額 | 時価総額（百万ドル） 1228.918 |
| 売上高 | 売上高（百万ドル） 187.00800 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1244.33 |
| 当期純利益 | 当期純利益（百万ドル） -19.14100 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 AtriCure Inc. revenues increased 14% to $98.8M. Net loss decreased 39% to $10.5M. Revenues reflect United States segment increase of 15% to $79.3M Europe segment increase of 16% to $12.6M. Lower net loss reflects Research and development expenses - Bala decrease of 4% to $16.8M (expense) Interest Income increase of 95% to $199K (income). |
ATRCのテクニカル分析
ATRCのニュース
Needham & Company maintains AtriCure at Buy with a price target of $60.00 2023/05/03 15:57:37 Investing.com
https://www.investing.com/news/pro/atricure-receives-investment-bank-analyst-rating-update-3071617
AtriCure, Inc. (ATRC) Q1 2023 Earnings Call Transcript 2023/05/03 01:40:06 Seeking Alpha
AtriCure, Inc. (NASDAQ:NASDAQ:ATRC) Q1 2023 Earnings Conference Call May 2, 2023 4:30 PM ETCompany ParticipantsMarissa Bych – Vice President-Gilmartin GroupMike Carrel – President and Chief…
AtriCure Non-GAAP EPS of -$0.23 beats by $0.12, revenue of $93.5M beats by $5.97M 2023/05/02 20:17:26 Seeking Alpha
AtriCure press release (ATRC): Q1 Non-GAAP EPS of -$0.23 beats by $0.12.Revenue of $93.5M (+25.4% Y/Y) beats by $5.97M.2023 Financial GuidanceFull year 2023 revenue is projected to…
AtriCure (ATRC) Presents At Oppenheimer 33rd Annual Health Conference - Slideshow 2023/03/21 15:06:46 Seeking Alpha
The following slide deck was published by AtriCure, Inc.
AtriCure, Inc. (ATRC) Q4 2022 Earnings Call Transcript 2023/02/22 03:47:06 Seeking Alpha
AtriCure, Inc. (NASDAQ:NASDAQ:ATRC) Q4 2022 Earnings Conference Call February 21, 2023 4:30 PM ETCompany ParticipantsMarissa Bych - Gilmartin Group, Investor RelationsMichael Carrel -…
AtriCure, Inc. (ATRC) Q4 2022 Earnings Call Transcript 2023/02/22 03:47:06 Seeking Alpha
AtriCure, Inc. (NASDAQ:NASDAQ:ATRC) Q4 2022 Earnings Conference Call February 21, 2023 4:30 PM ETCompany ParticipantsMarissa Bych - Gilmartin Group, Investor RelationsMichael Carrel -…
AtriCure: Q4 Earnings Snapshot 2023/02/21 21:13:33 WTOP
MASON, Ohio (AP) — MASON, Ohio (AP) — AtriCure Inc. (ATRC) on Tuesday reported a loss of $4.2 million in…
AtriCure GAAP EPS of -$0.09 beats by $0.09, revenue of $88M beats by $0.1M 2023/02/21 21:04:24 Seeking Alpha
AtriCure press release (ATRC): Q4 GAAP EPS of -$0.09 beats by $0.09.Revenue of $88M (+20.2% Y/Y) beats by $0.1M.Adjusted EBITDA was positive for the fourth quarter 2022 at $6.0…
AtriCure Reports Fourth Quarter 2022 and Full Year 2022 Financial Results 2023/02/21 21:00:00 Wallstreet:Online
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced fourth quarter 2022 and full year 2022 financial results. “We delivered another outstanding year of growth in 2022, as we expanded adoption across our broad portfolio of solutions. I
Earnings Outlook For AtriCure 2023/02/20 15:00:56 Benzinga
AtriCure (NASDAQ: ATRC ) is set to give its latest quarterly earnings report on Tuesday, 2023-02-21. Here''s what investors need to know before the announcement. Analysts estimate that AtriCure will report an earnings per share (EPS) of $-0.18. AtriCure bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next … Full story available on Benzinga.com
AtriCure (ATRC) Investor Presentation - Slideshow 2022/08/20 14:55:50 Seeking Alpha
The following slide deck was published by AtriCure, Inc.
AtriCure, Inc. (ATRC) CEO Mike Carrel on Q2 2022 Results - Earnings Call Transcript 2022/08/03 05:08:05 Seeking Alpha
AtriCure, Inc. (NASDAQ:NASDAQ:ATRC) Q2 2022 Earnings Conference Call August 2, 2022 16:30 ET Company Participants Marissa Bych - Investor Relations Mike Carrel - President and Chief…
AtriCure: Q2 Earnings Insights 2022/08/02 21:21:47 Benzinga
AtriCure (NASDAQ: ATRC ) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:01 PM. Here''s what investors need to know about the announcement. Earnings AtriCure missed estimated earnings by 10.34%, reporting an EPS of $-0.32 versus an estimate of $-0.29. Revenue was up $13.15 million from the same period last … Full story available on Benzinga.com
AtriCure GAAP EPS of -$0.32 misses by $0.03, revenue of $84.53M beats by $4.86M 2022/08/02 20:02:05 Seeking Alpha
AtriCure press release (ATRC): Q2 GAAP EPS of -$0.32 misses by $0.03.Revenue of $84.53M (+18.4% Y/Y) beats by $4.86M.
AtriCure Reports Second Quarter 2022 Financial Results 2022/08/02 20:00:00 Wallstreet:Online
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced second quarter 2022 financial results. “We delivered a remarkable second quarter as we continue changing the standard of care for millions of patients globally,” said Michael Carrel,